Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hoth Therapeutics

0.8700
-0.0290-3.23%
Volume:25.22K
Turnover:22.11K
Market Cap:11.46M
PE:-0.68
High:0.9000
Open:0.9000
Low:0.8656
Close:0.8990
Loading ...

Hoth Therapeutics responds to market rumors, says no plans for offering

TIPRANKS
·
09 Jan

Hoth Therapeutics affirms no plans for public, private offering at this time

TIPRANKS
·
09 Jan

Hoth Therapeutics: Strong balance sheet includes over $10M cash, no debt

TIPRANKS
·
09 Jan

Hoth Therapeutics: Enrollment in HT-001 trial proceeding as planned

TIPRANKS
·
09 Jan

BRIEF-Hoth Therapeutics Affirms That It Has No Plans For Public Or Private Offering At This Time

Reuters
·
09 Jan

Hoth Therapeutics: Affirms That It Has No Plans for a Public or Private Offering at This Time

THOMSON REUTERS
·
09 Jan

Hoth Therapeutics Inc - Qtrly

THOMSON REUTERS
·
09 Jan

Hoth Therapeutics: Enrollment in Ht-001 Clinical Trial Is Proceeding as Planned

THOMSON REUTERS
·
09 Jan

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

PR Newswire
·
09 Jan

HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Zacks
·
08 Jan

Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success

GuruFocus.com
·
08 Jan

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires Live
·
08 Jan

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
08 Jan

D. Boral says Hoth findings highlight HT-001 potential to ‘revolutionize’ care

TIPRANKS
·
08 Jan

Hoth Therapeutics Shares Hit 52-Week High on Positive Data for Cancer Treatment

Dow Jones
·
07 Jan

Hoth Therapeutics Says Interim Trial Results Show Drug to Mitigate Skin Cancer Treatment Toxicity Met Efficacy Endpoint

MT Newswires Live
·
07 Jan

Hoth Therapeutics Shares up 83% on Positive Mid-Stage Trial Data for Skin Toxicity Treatment

THOMSON REUTERS
·
07 Jan

BUZZ-Hoth Therapeutics rises on positive mid-stage trial data for skin toxicity treatment

Reuters
·
07 Jan

Hoth Therapeutics reports ‘encouraging’ results from Phase 2a trial of HT-001

TIPRANKS
·
07 Jan

Hoth Therapeutics Inc - Preserves Cancer Treatment Efficacy With Zero Dose Reductions

THOMSON REUTERS
·
07 Jan